1990
DOI: 10.1093/infdis/161.1.27
|View full text |Cite
|
Sign up to set email alerts
|

A Recombinant Human Adenovirus Vaccine against Rabies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
58
1

Year Published

1995
1995
2009
2009

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 128 publications
(62 citation statements)
references
References 14 publications
2
58
1
Order By: Relevance
“…Adenoviruses are distributed worldwide and infections with human adenovirus serotype 5 do not result in serious disease (Rowe et al, 1955;Andiman and Miller, 1982;Charlton et al, 1992;Russell, 1998). Human adenoviruses are currently being utilized in vaccine development due to their genetic stability and ability to be grown to high titers in a variety of cell types (Prevec et al, 1990), and they are being considered to serve as vectors for human vaccination and gene therapy (Bonnekoh et al, 1998;MolinierFrenkel et al, 2000;Flotte, 2004). There are no perceived environmental or public heath impacts of distributing ONRABH in Ontario, or elsewhere, because the vaccine has been extensively safety tested and as shown in this study there were very few human or companion animal contacts with the vaccine and no adverse reactions noted.…”
Section: Discussionmentioning
confidence: 99%
“…Adenoviruses are distributed worldwide and infections with human adenovirus serotype 5 do not result in serious disease (Rowe et al, 1955;Andiman and Miller, 1982;Charlton et al, 1992;Russell, 1998). Human adenoviruses are currently being utilized in vaccine development due to their genetic stability and ability to be grown to high titers in a variety of cell types (Prevec et al, 1990), and they are being considered to serve as vectors for human vaccination and gene therapy (Bonnekoh et al, 1998;MolinierFrenkel et al, 2000;Flotte, 2004). There are no perceived environmental or public heath impacts of distributing ONRABH in Ontario, or elsewhere, because the vaccine has been extensively safety tested and as shown in this study there were very few human or companion animal contacts with the vaccine and no adverse reactions noted.…”
Section: Discussionmentioning
confidence: 99%
“…Most of the past efforts focused on human Ads, such as those of the common serotype 5 (AdHu5), which cause mild upper respiratory symptoms upon natural infections. Both replication competent 9,10 and E1-deleted (DE1) replication-defective AdHu5 vectors have been developed as vaccine carriers and have shown efficacy in mice, 11 dogs 12,13 and nonhuman primates (NHPs). 7 E1-deleted AdHu5 vectors also performed well in clinical trials.…”
Section: Introductionmentioning
confidence: 99%
“…The potential of various adenoviruses as vectors for recombinant virus vaccines and somatic gene therapy is currently being extensively investigated (Chanda et al, 1990;Graham, 1990;Prevec et al, 1990;Rosenfeld et al, 1992;Mittal et al, 1994Mittal et al, , 1995Ragot et al, 1993;Engelhardt et al, 1994). Most of these studies are based on the use of human adenovirus type 5 (HAd5) as a foreign gene expression vector in mammalian cells.…”
Section: Introductionmentioning
confidence: 99%